换一批
换一批Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?
作者：
主题词
人类(Humans);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质c-abl(Proto-Oncogene Proteins c-abl);原癌基因蛋白质c-bcr(Proto-Oncogene Proteins c-bcr);随机对照试验(主题)(Randomized Controlled Trials as Topic);缓解诱导(Remission Induction);时间因素(Time Factors);治疗结果(Treatment Outcome);停止治疗(Withholding Treatment)
DOI
10.1111/bcp.13637
PMID
29862545
发布时间
2021-01-09
- 浏览24
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
